Author's response to reviews

Title: Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study

Authors:

Sasja F Mulder (Sasja.Mulder@radboudumc.nl)
Dirk Bertens (d.bertens@donders.ru.nl)
Ingrid M.E. Desar (Ingrid.Desar@radboudumc.nl)
Kris C.P. Vissers (Kris.Vissers@radboudumc.nl)
Peter F.A. Mulders (Peter.Mulders@radboudumc.nl)
Cornelis J.A. Punt (c.punt@amc.uva.nl)
Dick-Johan van Spronsen (d.j.v.spronsen@cwz.nl)
Johan F Langenhuijsen (Hans.Langenhuijsen@radboudumc.nl)
Roy P.C. Kessels (Roy.Kessels@radboudumc.nl)
Carla M.L. van Herpen (Carla.vanHerpen@radboudumc.nl)

Version: 3
Date: 23 December 2013

Author's response to reviews: see over
Author’s response to reviews

Title: Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study

Authors:
Sasja F. Mulder (Sasja.Mulder@radboudumc.nl)
Dirk Bertens (d.bertens@donders.ru.nl)
Ingrid M.E. Desar (Ingrid.Desar@radboudumc.nl)
Kris C.P. Vissers (Kris.Vissers@radboudumc.nl)
Peter F.A. Mulders (Peter.Mulders@radboudumc.nl)
Cornelis J.A. Punt (c.punt@amc.uva.nl)
Dick-Johan van Spronsen (d.j.v.sprousen@cwz.nl)
Johan F. Langenhuijsen (Hans.Langenhuijsen@radboudumc.nl)
Roy P.C. Kessels (Roy.Kessels@radboudumc.nl)
Carla M.L. van Herpen (Carla.vanHerpen@onco.umcn.nl)

Version: 3  Date: 13 December 2013
Author’s response to reviews: see over

We would like to thank the reviewers for their comments. We have tried to answer questions in an appropriate way.

As requested we added the full name of the Ethics committee that approved the study and we included the trial registration number at the end of the abstract.
Reviewer's report

Title: Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study

Version: 2 Date: 21 October 2013

Reviewer: Alexandre Chan

Reviewer's report:
Major Compulsory Revision
The authors have addressed most of the methodological concerns that we have raised in the original paper. In the discussion, however, authors have not discussed the biological basis (i.e. how VEGF potentially affect cognition) based on the current understanding. There is a review paper that was recently published on this issue. The authors should incorporate such discussions citing this most recent paper available


Answer: We incorporated the results of this recent review in the discussion

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Answer: we made language corrections.

Statistical review: No, the manuscript does not need to be seen by a statistician.
Reviewer's report

Title: Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study

Version: 2 Date: 4 November 2013

Reviewer: Martin Klein

Reviewer's report:
I think the authors incorporated this reviewers' comments in a satisfactory way and I think the manuscript in its present form adds to the scarce scientific literature in this field.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician

Answer: no alterations were requested.